HAVIT Blog
Science-backed guides on habits, sleep, nutrition, and movement.
All articles
Retatrutide Tracker: What It Is & What to Track (2026)
A retatrutide tracker guide: what the investigational triple agonist is, trial results so far (~24% weight loss in Phase 2), its status, and what you'd track.
Semaglutide Side Effects: Ozempic, Wegovy & Rybelsus (2026)
Semaglutide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Frequency depends on the product and dose: highest with Wegovy 2.4 mg (weight loss), lower with Ozempic and oral Rybelsus (diabetes). Rare serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
Semaglutide Tracker: What to Track (Ozempic, Wegovy, Rybelsus)
A semaglutide tracker logs your dose, injection site or pill timing, weight trend, protein & side effects across Ozempic, Wegovy & Rybelsus. Here's what to track.
Shotsy Alternative for GLP-1 Users: An Honest 2026 Comparison — Havit vs Shotsy
Looking for a Shotsy alternative on Ozempic or Zepbound? What Shotsy's shot tracker does well, where it stops, and how an all-in-one GLP-1 app compares.
Tirzepatide Side Effects: Mounjaro & Zepbound (2026)
The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent medical care.
Tirzepatide Tracker: What to Track on Mounjaro & Zepbound
A tirzepatide tracker logs your weekly dose, injection site, weight trend, protein & side effects — for Mounjaro or Zepbound. Learn what to track and why.
Wegovy Side Effects: Nausea, Hair Loss & Timeline (2026)
Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Because Wegovy titrates to a higher 2.4 mg dose, these are reported more often than with Ozempic. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.
Wegovy Tracker: What to Track on Wegovy & How (2026)
A Wegovy tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on semaglutide and why it matters.
WeightWatchers GLP-1 Alternative: An Honest 2026 Comparison — Havit vs WeightWatchers
Looking for a WeightWatchers GLP-1 alternative? What WW's Points program and WeightWatchers Clinic do well, where they leave gaps, and how to choose a tracker.
Zepbound Side Effects: Nausea, Hair Loss & Timeline (2026)
Zepbound's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Injection-site reactions and hair loss are also labeled. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.
Zepbound Tracker: What to Track on Zepbound & How (2026)
A Zepbound tracker logs your dose date, injection site, weight trend, protein & side effects. Learn exactly what to track on tirzepatide and why it matters.
GLP-1 Alone Is Not Enough — The "Drug + Behavioral Therapy" Model Recommended by WHO/ADA, and HAVIT's M0/M1/M2 Stages
GLP-1 receptor agonists (Wegovy, Mounjaro, Zepbound) produce 15–22% average weight loss (STEP 1, SURMOUNT-1). But STEP 4 reported +11.6%p regain one year after discontinuation — about 78% of weight loss returned. WHO (2022) and ADA Standards (2024) explicitly recommend behavioral therapy alongside pharmacotherapy, and STEP 3 (JAMA 2021) showed Intensive Behavioral Therapy in combination achieved nearly 3× the weight loss of standard-care combination (−16% vs −5.7%). HAVIT structures this in 3 stages — pre-medication (M0), adaptation (M1), maintenance/discontinuation (M2) — integrating drugs, muscle preservation, and behavior learning. HAVIT does not prescribe GLP-1; prescription, dosing, and discontinuation remain the physician's domain.
